FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Court Backs FDA Lumryz Approval

The DC federal court tosses a Jazz Pharmaceuticals suit against FDA over the agencys approval of Avadels narcolepsy drug Lumryz before the end of the ...

latest-news-card-1
Federal Register

Guides on Bioequivalence Study Designs

Federal Register notice: FDA makes available a final guidance entitled M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms and a supplem...

latest-news-card-1
Human Drugs

FDA: Compounders Should Use Suitable Ingredients

FDA reminds drug compounders to only use ingredients that are suitable for compounding drugs intended to be sterile.

latest-news-card-1
Human Drugs

FDA Extends Some Baxter Parenteral Drug Product Use Dates

FDA announces extended use dates for some Baxter parenteral products to ease supply issues caused when a Baxter North Carolina facility was hit by Hur...

latest-news-card-1
Human Drugs

Warning on Skin-Cap Spray Products

FDA warns that Chemigroup France is marketing Skin-Cap aerosol spray products that may contain undisclosed steroids.

latest-news-card-1
Human Drugs

Exactech 3D-Printed Knee Implant Cleared

FDA clears an Exactech 510(k) for the Truliant Porous Tibial Tray, a 3D-printed tibial knee implant.

latest-news-card-1
Human Drugs

Imbed Bio Lidocaine Wound Dressing Cleared

FDA clears an Imbed Biosciences 510(k) for its Microlyte Ag/Lidocaine, an antimicrobial wound dressing that integrates lidocaine for managing painful ...

latest-news-card-1

Use Risk-Based AI/ML Regulation: AstraZeneca

AstraZeneca provides four comments to the FDA docket on considerations for generative artificial intelligence/machine learning over a medical devices ...

latest-news-card-1
Medical Devices

Datex-Ohmeda Recalls Giraffe OmniBeds

GE HealthCare subsidiary Datex-Ohmeda recalls its Giraffe OmniBed and Giraffe OmniBed CareStation to update their use instructions.

latest-news-card-1
Human Drugs

UCBs Bepranemab Misses Primary Endpoint

UCB says its investigational Alzheimers drug bepranemab missed the primary endpoint in a Phase 2a trial but hit secondary endpoints in some patient su...